YKL-40 Correlates with Soluble CD 40 Ligand in Old Myocardial Infarction with Hypertension
Abstract
BACKGROUND: Myocardial infarction is one of the coronary artery diseases caused by plaque rupture, plaque erosion or calcified nodules, with the occurence of thrombus formation and artery occlusion. YKL-40 has a functional role in plaque fibrous formation because of its high expression during fibrosis development, vascular smooth muscle cells differentiation, elevated matrix turnover and tissue remodelling in old myocardial infarction, whereas CD40 ligand, which is stored in the cytoplasm of resting platelets, rapidly presents on the surface. After cleavage, a soluble functional CD40 ligand (sCD4OL) is generated. The aim of this study was to assess the association between YKL-40 and sCD4OL in old myocardial infarction.
METHODS: This study used the cross sectional study design. Fifty six patients with old myocardial infarction were selected based on their electrocardiographical results. Among these patients, 23 subjects had hypertension and 15 subjects had hsCRP >3-l0 mg/L. YKL-40 and sCD40L were measured by ELISA method.
RESULTS: There was no significant correlation between YKL-40 and sCD40L (r=0.078; p=0.569) in old myocardial infarction and in subjects with hsCRP >3-10 mg/L (r=0.524; p=0.045). However, significant positive correlations Were found in subjects with hypertension (r=0.447; p=0.029).
CONCLUSIONS: Our findings showed that YKL 40 correlated significantly with sCD4OL in subjects with hypertension.
KEYWORDS: myocardial infarction, ruptured plaque, coronary artery disease, YKL-40, soluble CD40 ligand
Full Text:
PDFReferences
Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global burden of disease study. Lancet. 1997; 349: 1436-42, CrossRef.
Majid A. Coronary heart disease: Pathophysiology, prevention and current treatment. In: Inauguration Speech Professor of Fixed Position in the Field of Science Physiology at the Faculty of Medicine. Medan: Universitas Sumater Utara; 2007.
Naghavi M, Libby P, Falk E, Casscells W, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient - a call for new definitions and risk assessment strategies: part I. Circulation. 2003; 108: 1664-72, CrossRef.
Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol. 2006; 47: C13-8, CrossRef.
Lafont A. Basic aspects of plaque vulnerability. Heart. 2003; 89: 1262-67, CrossRef.
Shackelton LM, Mann DM, Millis AJ. Identification of a 38-kDa heparin-binding lycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem. 1995; 270: 13076-83, CrossRef.
Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretary product of articular chondrocytes and synovial cells, is a mammalian member of chitinase protein family. Biochem J. 1993; 268: 25803-10, PMID.
Ling H, Recklies AD. The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha. Biochem J. 2004; 380: 651-9, CrossRef.
Recklies AD, White C, Ling H. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J. 2002; 365: 119-26, CrossRef.
Kucur M, Isman KF, Karadag B, Vural VA, Tavsanoglu S. Serum YKL-40 concentrations in patient with coronary artery disease. Coronary Artery Disease. 2007; 18: 391-6, CrossRef.
Nojgaard C, Host NB, Christensen J, Poulsen SH, Egstrup K, Price PA, et al. Serum concentrations of YKL-40 in patients with acute myocardial infarction. Coronary Artery Disease. 2008; 19: 257-63, CrossRef.
Davi G, Patrono C. Platelet activation and aterothrombosis. N Engl J Med. 2007; 357: 2482-94, CrossRef.
Heeschen C, Dimmeler S, Hamm CW, Brand MJ, Boersma E, Zeiher AM, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003; 348: 1104-11, CrossRef.
Nojgaard C, Johansen JS, Christensen E, Skovgaard LT, Price PA, Becker U. Serum concentrations of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol. 2003; 39: 179-86, CrossRef.
Johansen JS, Christoffersen P, Moller S, Price PA, Henriksen JH, Garbarsch C, et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol. 2000; 32: 911-20, CrossRef.
Malinda KM, Ponce L, Kleinman HK, Shackelton LM, Millis AJT. Gp38k, a protein synthesized by vascular smooth muscle cells stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res. 1999; 250: 168-73, CrossRef.
Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74, CrossRef.
Naghavi M, Libby P, Falk E, Casscells W, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient - a call for new definitions and risk assessment strategies: part II. Circulation. 2003; 108: 1772-8, CrossRef.
Kit Insert Glucose (Glucse/HK). Roche Hitachi (2008-09, V7 English).
Kit Insert ALT (ALAT/GPT). Roche (2007-12, V10 English).
DOI: https://doi.org/10.18585/inabj.v4i1.159
Copyright (c) 2012 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
